Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,340 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,701 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02436044 | HAIC Using Oxaliplatin Plus Fluorouracil/Leucovorin for Patients With Locally Advanced HCC | approved for marketing | — | — | Ming ZhaoOTHER | 1 | Aug 20, 2019 | clinicaltrials |
| NCT00684385 | An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck | approved for marketing | — | — | AstraZenecaINDUSTRY | 4 | Mar 14, 2019 | clinicaltrials |
| NCT02477891 | Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma | approved for marketing | — | — | Janssen Research & Development, LLCINDUSTRY | 6 | Jan 15, 2019 | clinicaltrials |
| NCT03533361 | Expanded Access Program With Lenvatinib for the Treatment of Differentiated Thyroid Cancer in Brazil | approved for marketing | — | — | Eisai Inc.INDUSTRY | 1 | Dec 17, 2018 | clinicaltrials |
| NCT01931306 | Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC) | approved for marketing | — | — | Boehringer IngelheimINDUSTRY | 1 | Nov 14, 2018 | clinicaltrials |
| NCT00683306 | Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment | approved for marketing | — | — | AstraZenecaINDUSTRY | 19 | Sep 13, 2018 | clinicaltrials |
| NCT03245424 | Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation | approved for marketing | — | — | Agios Pharmaceuticals, Inc.INDUSTRY | 0 | Jul 24, 2018 | clinicaltrials |
| NCT02705313 | EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx | approved for marketing | — | — | Advanced Accelerator ApplicationsINDUSTRY | 1 | Apr 9, 2018 | clinicaltrials |
| NCT01869803 | Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia | approved for marketing | — | — | Wake Forest University Health SciencesOTHER | 1 | Mar 2, 2018 | clinicaltrials |
| NCT01592136 | Expanded Access Program of Ponatinib | approved for marketing | — | — | Ariad PharmaceuticalsINDUSTRY | 1 | Feb 6, 2018 | clinicaltrials |
| NCT02792725 | Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer | approved for marketing | — | — | Eli Lilly and CompanyINDUSTRY | 1 | Oct 31, 2017 | clinicaltrials |
| NCT03079687 | Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer. | approved for marketing | — | — | AstraZenecaINDUSTRY | 1 | Oct 25, 2017 | clinicaltrials |
| NCT01410500 | Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease | approved for marketing | — | — | AmgenINDUSTRY | 0 | May 2, 2017 | clinicaltrials |
| NCT03025867 | Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer | approved for marketing | — | — | Tesaro, Inc.INDUSTRY | 0 | Apr 17, 2017 | clinicaltrials |
| NCT02437019 | Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | approved for marketing | — | — | Janssen-Cilag Farmaceutica Ltda.INDUSTRY | 1 | Mar 20, 2017 | clinicaltrials |
| NCT01606982 | Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy | approved for marketing | — | — | Astellas Pharma Global Development, Inc.INDUSTRY | 0 | Feb 17, 2017 | clinicaltrials |
| NCT02355054 | Detecting Recurrent Prostate Cancer With C-11 Choline Positron Emission Tomography: An Expanded Access Study | approved for marketing | — | — | Washington University School of MedicineOTHER | 1 | Jan 20, 2017 | clinicaltrials |
| NCT01649284 | Afatinib Expanded Access Program | approved for marketing | — | — | Boehringer IngelheimINDUSTRY | 1 | Nov 30, 2016 | clinicaltrials |
| NCT01209650 | LUX Lung Special Access Scheme Australia Named Patient Use (NPU) | approved for marketing | — | — | Boehringer IngelheimINDUSTRY | 1 | Nov 10, 2016 | clinicaltrials |
| NCT02589717 | An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy | approved for marketing | — | — | Genentech, Inc.INDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01160250 | A Study of Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma | approved for marketing | — | — | Genentech, Inc.INDUSTRY | 1 | Aug 6, 2015 | clinicaltrials |
| NCT01240421 | An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory | approved for marketing | — | — | Eisai Inc.INDUSTRY | 3 | May 22, 2015 | clinicaltrials |
| NCT02136511 | Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia | approved for marketing | — | — | Gilead SciencesINDUSTRY | 4 | Oct 28, 2014 | clinicaltrials |
| NCT01683110 | Expanded Access of Cabozantinib in Medullary Thyroid Cancer | approved for marketing | — | — | ExelixisINDUSTRY | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00905593 | Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase(ENACT) | approved for marketing | — | — | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 18, 2012 | clinicaltrials |
| NCT00130897 | Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma | approved for marketing | — | — | PfizerINDUSTRY | 50 | Mar 9, 2012 | clinicaltrials |
| NCT00730444 | Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma | approved for marketing | — | — | GE HealthcareINDUSTRY | 1 | Nov 9, 2009 | clinicaltrials |
| NCT00786058 | A Phase III Second Line Trial in Advanced Pancreatic Cancer CONKO 003 | approved for marketing | — | — | CONKO-StudiengruppeOTHER | 0 | Jun 15, 2009 | clinicaltrials |
| NCT00040625 | ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma. | approved for marketing | — | — | Eli Lilly and CompanyINDUSTRY | 4 | Mar 15, 2007 | clinicaltrials |
Data updated 22 days agoSource updated Aug 20, 2019source: clinicaltrials